All posts by medical

Moderna and Merck’s V940 Plus Pembrolizumab Demonstrates Improvement in RFS and DMFS in Stage III/IV … – Dermatology Times

Superficial spreading melanoma

Image courtesy of DermNet

Moderna and Merck recently announced follow-up data from the phase 2b randomized KEYNOTE-942/mRNA-4157-P201 study, a clinical trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with pembrolizumab (Keytruda), Merck's anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV) following complete resection. After a follow-up of 3 years, adjuvant treatment with V940 plus pembrolizumab continued to demonstrate a clinically meaningful improvement in recurrence-free survival (RFS), reducing the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) compared with pembrolizumab alone. V940 plus pembrolizumab also continued to demonstrate a meaningful improvement in distant metastasis-free survival (DMFS), compared with pembrolizumab alone, reducing the risk of developing distant metastasis or death by 62% (HR=0.384 [95% CI, 0.172-0.858]; one-sided nominal p= 0.0077).

Based on data from the phase 2b KEYNOTE-942/mRNA-4157-P201 study, the FDA and European Medicines Agency granted Breakthrough Therapy Designation and the Priority Medicines (PRIME) scheme, respectively, for V940 plus pembrolizumab for the adjuvant treatment of patients with high-risk melanoma.

"As we continue to follow participants in the KEYNOTE-942/mRNA-4157-P201 study, we are excited to see such a robust clinical benefit with mRNA-4157 (V940) as adjuvant treatment in combination with KEYTRUDA in people with resected high-risk melanoma," said Kyle Holen, MD, the senior vice president and head of development of therapeutics and oncology at Moderna, in the news release. "These data add another positive analysis to the multiple endpoints and subgroups previously assessed in this study. Importantly for this technology, the KEYNOTE-942/mRNA-4157-P201 study was the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial and the first combination therapy to show a significant benefit over KEYTRUDA alone in adjuvant melanoma. We look forward to sharing these data with people impacted by this disease and the broader scientific community."

Adverse events observed with V940 in KEYNOTE-942 are similar to those previously reported. At a median planned follow-up of approximately 3 years, the number of patients reporting treatment-related grade 3 adverse events was similar between the arms (25% for V940 plus pembrolizumab vs 20% for pembrolizumab alone). The most common adverse events associated with V940 were fatigue (60.6%), injection site pain (56.7%), and chills (49%).

In July 2023, Moderna and Merck announced the initiation of a pivotal phase 3 randomized INTerpath-001 (NCT05933577) clinical trial evaluating V940 plus pembrolizumab, as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) melanoma. Global recruitment in INTerpath-001 has started.

"We are committed to driving research forward for innovative modalities in earlier stages of cancer, where we can make the most meaningful impact for patients, by combining Merck's expertise in immuno-oncology with Moderna's innovative mRNA technology," said Marjorie Green, MD, the senior vice president and head of late-stage oncology and global clinical development at Merck Research Laboratories, in the news release. "We are pleased to see the results from this planned analyses on recurrence-free survival for V940 (mRNA-4157), and look forward to working with Moderna in expanding our clinical development program for the individualized neoantigen therapy."

Reference

Moderna and Merck announce mRNA-4157 (v940) in combination with Keytruda(r) (pembrolizumab) demonstrated continued improvement in recurrence-free survival and distant metastasis-free survival in patients with high-risk stage iii/iv melanoma following complete resection versus Keytruda at three years. News release. Moderna. December 14, 2023. Accessed December 18, 2023. https://investors.modernatx.com/news/news-details/2023/Moderna-And-Merck-Announce-mRNA-4157-V940-In-Combination-with-KeytrudaR-Pembrolizumab-Demonstrated-Continued-Improvement-in-Recurrence-Free-Survival-and-Distant-Metastasis-Free-Survival-in-Patients-with-High-Risk-Stage-IIIIV-Melanoma-Following-Comple/default.aspx

Read the rest here:

Moderna and Merck's V940 Plus Pembrolizumab Demonstrates Improvement in RFS and DMFS in Stage III/IV ... - Dermatology Times

Aptar Digital Health and Legit.Health Partner to Improve Patient Experience in Immuno-Dermatology – Healthcare Packaging

This content was written and submitted by the supplier. It has only been modified to comply with this publications space and style.

Aptar Digital Health, a developer of Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs), and disease management solutions, has announced a new partnership with Legit.Health, an artificial intelligence-based, medical device software company that focuses on the early detection, evaluation, and monitoring of skin diseases.

Legit.Healths technology, which supports the diagnosis of approximately 300 conditions including atopic dermatitis, psoriasis, and skin cancer, will be integrated into Aptar's Digital Health proprietary platform. Focused on enhancing patient care and increasing patient autonomy, this advanced digital solution will support healthcare professionals (HCPs) to diagnose skin conditions earlier and will enable patients to start treatment plans sooner to improve their overall quality of life. The solution also may be used to facilitate patient enrollment in clinical trials.

Legit.Health's use of AI for monitoring disease progression through automated, clinically validated scoring systems, such as the Psoriasis Area Severity Index (PASI) and SCORing Atopic Dermatitis (SCORAD), will be leveraged within this partnership. This will help to ensure patients receive the most accurate and timely information to manage and treat their skin condition more effectively. The AI-powered technology also extends to the quantification of the intensity, count, and extent of the visible clinical signs of skin conditions, offering HCPs a more precise measure of disease severity, an indicator considered critical in determining the most appropriate treatment.

This strategic partnership is set to drive digital transformation in the healthcare sector. Aptar Digital Health andLegit.Healthtogether will pave the way towards harnessing the power of AI to improve patient experiences and outcomes in immuno-dermatology.

Sai Shankar, President, Aptar Digital Health, stated, Since 2021, Aptar Digital Health has been growing our portfolio of technology partners to provide improved solutions for patients in multiple therapeutic areas such as cardiology, neurology and visual acuity. With this new partnership, Aptar Digital Health is acquiring the ability to leverage AI technology to accelerate the diagnosis and monitoring of skin conditions.

Andy Aguilar, CEO and Co-Founder ofLegit.Health, commented, One of our main aims within the medical assistance process in the field of dermatology is to be able to offer patients the opportunity of having the earliest and most accurate diagnosis, with the appropriate referral and treatment to reduce uncertainty and waiting times. She added, Legit.Health's technology helps the medical practitioner to provide this kind of care to their patients and today, thanks to our partnership with Aptar Digital Health, we will be able to reach even more people who will benefit from our service

See original here:

Aptar Digital Health and Legit.Health Partner to Improve Patient Experience in Immuno-Dermatology - Healthcare Packaging

Navigating Location Specific Treatment Selection and Topical Therapy Limitations – Dermatology Times

This is a video synopsis/summary of a panel discussion involving Lisa Swanson, MD, FAAD, and Robert J. Casquejo, PA-C.

The conversation begins with an exploration of the distinctive features of plaque psoriasis that differentiate it from other dermatologic conditions. The difficulty of diagnosing psoriasis is discussed, with attention to variables like location, skin color, and ethnic variability. The challenges become apparent when distinguishing between psoriasis and conditions such as eczema.

The speakers note that psoriasis diagnosis can be straightforward in some cases but challenging in others, particularly when there is an overlap with conditions like eczema. An expert shares experiences from his pediatric specialty, highlighting instances where psoriasis is misdiagnosed as other dermatologic conditions.

The conversation shifts to the significance of the location of psoriasis involvement in guiding treatment decisions. Scalp psoriasis is emphasized as a challenging area for topical management, prompting considerations of both physical and psychosocial impact. An expert discusses his approach, focusing on the severity of physical symptoms and the psychosocial impact when deciding on treatment options.

The speakers delve into the challenges of managing scalp psoriasis with topical medications, noting issues like greasiness and patient dissatisfaction. An expert suggests that systemic treatment options may be more practical for areas like the scalp due to ease of use and patient preferences.

The speakers agree on the complexity of treating psoriasis in problematic areas like the scalp, acknowledging the limitations of topical medications and the need for more aggressive approaches. The conversation concludes with an acknowledgment that certain areas, including the scalp, pose challenges that may require systemic treatments beyond topical applications.

Video synopsis is AI-generated and reviewed by DermatologyTimes editorial staff.

Read more:

Navigating Location Specific Treatment Selection and Topical Therapy Limitations - Dermatology Times

Research Team Led By Dr. Gunisha Kaur Wins 2023 National Academy of Medicine Catalyst Prize – Weill Cornell Medicine Newsroom

Anesthesiologist and global health expert Dr. Gunisha Kaur and her research team recently won a prestigious National Academy of Medicine (NAM) Catalyst Prize.

The Catalyst Awards are a branch of the Healthy Longevity Global Competition that seeks to expand the human healthspanusually defined as how many healthy years a person livesby rewarding cutting-edge ideas to improve the physical, mental, or social wellbeing and health of people as they age. Up to 20 awards are being given this year to United States-based innovators, out of 1,100 applications received from organizations focused on science, medicine, and health, to technology, finance, social sciences, and beyond, NAM said.

NAM works with eight global collaborators that represent more than 50 countries and territories, all of which issued their own Catalyst Awards on the same day.

Dr. Kaurs team won the prize for its project, Digital Solutions to Reduce Maternal Morbidity and Mortality in Refugee Women, which aims to clinically train and validate a digital refugee health system. The prize comes with $50,000 of seed funding and networking opportunities and makes them eligible for the next phases of the competition. Two other phases of application and awards follow, with a $5 million grand prize.

Project lead author Dr. Kaur is an associate professor of anesthesiology at Weill Cornell Medicine, director of the Weill Cornell Medicine Human Rights Impact Lab, and a medical director of the Weill Cornell Center for Human Rights, which provides forensic medical evaluations to people who seek asylum in the United States. For this project, she collaborated with Stephen Yale-Loehr, a professor of immigration law practice at Cornell Law School, and Dr. Richard Boyer, an assistant professor of anesthesiology at Weill Cornell Medicine and a core director at the Human Rights Impact Lab. The lab interfaces with the Center for Human Rights, conducting research to advance the health of refugees and displaced populations.

The project involves a wearable device plus a customized app for early risk stratification and identification of gestational hypertension and preeclampsia, which are pregnancy complications.

All pregnant refugee women are at elevated risk for developing these complications because of barriers that can prevent refugees from accessing in-person health care. Dr. Kaur shared that interviews with refugee patients revealed many didnt access health care services because they believed erroneously that doing so would violate the law. Having an expert in immigration law, such as Yale-Loehr on the team, allows them to tell refugee women that since they are pregnant, they are allowed to access care such as prenatal visits and vaccines.

Many refugees and asylum seekers worry that if they seek medical help while pregnant, they might be deported," Yale-Loehr said. "This new research builds on prior work Dr. Kaur and I did dispelling that concern. Our website Rights4Health informs immigrants about their eligibility for public benefits.

As faculty fellows at theMario Einaudi Center for International Studies, Dr. Kaur and Yale-Loehr also lead a team researching refugee and immigrant health as part of Global CornellsMigrations: A Global Grand Challengeinitiative.

Even with very few other resources, almost all or 90 percent have a cell phone, which gives us an enormous opportunity to disseminate health care information about pregnancy and prenatal visits, and vaccines, she said.

The project also utilizes related biomarkers using predictive machine learning, ecological momentary assessments, and remote digital data for risk stratification and possible diagnosis, she said.

Our idea is to bring health care to refugee women through the use of cutting-edge digital technologies, said Dr. Kaur. If we can improve health care access, we can start to look at improving disease diagnosis and treatment.

Digital tools can help detect hypertension with high precision and can risk stratify for preeclampsia, so pregnant women with these conditions can be treated earlier in their pregnancies, she said. They have been used in landmark research studies such as the electronic Framingham Heart Study, but she wants to know exactly how they can be optimized for this patient population.

Thats what this study is about: Can we train our digital tools to do it as well as a clinic visit? she said. While these patients do not typically attend clinic visits, over 90 percent of them do have access to digital tools.

This project expands on work the team has done with digital technology in the last few years, but on an accelerated timeline: results need to be generated within 18 months.

Dr. Kaur remains consistently motivated about her work, she said. First, she believes it is the humane thing to do to provide refugees who have survived forced displacement appropriate and adequate medical care. Because her family came to America this way, she has a personal relationship with the medicine and science of this population and has developed a passion and drive to make a difference that manifests in this project.

The refugees and asylum seekers that we work with in our clinic and lab are people just like you, and just like me, Dr. Kaur said. Recognizing that shared humanityparticularly that there is very little that distinguishes between us and themhelps us to understand why this work is so important.

Follow this link:

Research Team Led By Dr. Gunisha Kaur Wins 2023 National Academy of Medicine Catalyst Prize - Weill Cornell Medicine Newsroom

Cells Move in Groups Differently Than They Do When Alone – NYU Langone Health

A protein that in single cells helps generate the force needed to move works differently in cells moving in groups, a new study shows.

Cells push and pull on each other and the surrounding tissue to move as they form organs in an embryo, heal wounds, track down invading bacteria, and even become cancerous and spread. Led by researchers at NYU Grossman School of Medicine, the new study examined how forces are generated by a group of 140 cells called the primordium that adhere to each other as they move into place in zebrafish embryos. Zebrafish are a major model in the study of development because they are transparent and share cellular mechanisms with humans.

Published online December 13 in Current Biology, the new work reveals how the cells in the primordium use a protein called RhoA to trigger forces that move the group in a developing embryo. To move, cells push out part of themselves called protrusions, use the protrusions to hold on to nearby tissues, and then haul them back in, as if casting out and hauling in an anchor to move forward.

VIDEO: A group of cells moves toward its correct final position in the tail of a forming zebrafish embryo. Cell membranes are green and the cell nuclei red.

This finding surprised us because we had no reason to suspect that the RhoA machinery required to move groups of cells would be different from that used by single cells, said senior study author Holger Knaut, PhD, associate professor in the Department of Cell Biology at NYU Langone Health.

Past studies had shown that single cells move forward in part by activating RhoA at their back ends. Active RhoA turns on the motor protein non-muscle myosin II, which causes the back ends of the cells to constrict and let go of the surface they are moving along on.

The current study found that the cells in the primordium instead activate RhoA in pulses in the front of the cells, where it does two jobs. At the front tip of the cell, RhoA grows the cell skeleton, called the actin meshwork, outward, forming protrusions that grip the surface. At the base of protrusions, RhoA triggers non-muscle myosin II to pull on the actin meshwork and haul in the protrusions. The pulling by myosin II makes the actin flow toward the center and back of the cells, pushing the cell group forward the way a banana slug moves along the ground.

Our findings suggest that RhoA-induced actin flow on the basal sides of cells constitutes the motor that pulls the primordium forward, a scenario that likely underlies the movement of many cell groups, added Dr. Knaut. The machinery suggests that the movement of single cells and groups of cells is similar, but that RhoA contributes to that machinery differently in each case. Within moving cell groups, RhoA generates actin flow directed toward the rear to propel the group forward.

Dr. Knaut notes that a better understanding of the mechanisms by which cell groups move has the potential to be useful in stopping the spread of cancer, perhaps by guiding the design of treatments that block the action of proteins noted in the study.

Along with Dr. Knaut, NYU Langone study authors were the co-corresponding author Weiyi Qian, PhD, Naoya Yamaguchi, and Patrycja Lis in the Department of Cell Biology, and Michael Cammer from the Microscopy Laboratory. The study was funded by Perlmutter Cancer Center Support Grant P30CA016087, National Institutes of Health grant R01NS119449, NYSTEM training grants C322560GG and C322560GG, two American Heart Association fellowships, 903886 and 20PRE3518016, and the NYU Deans Undergraduate Research Fund.

Greg Williams Phone: 212-404-3500 Gregory.Williams@NYULangone.org

See the original post here:
Cells Move in Groups Differently Than They Do When Alone - NYU Langone Health

Cells move in groups differently than they do when alone – EurekAlert

video:

Pictured here is a group of cells moving toward its correct final position in the tail of a forming zebrafish embryo. Cell membranes are green and the cell nuclei red.

Credit: Credit Holger Knaut, NYU Langone Health

A protein that helps generate the force needed for single cells to move works differently in cells moving in groups, a new study shows.

Cells push and pull on each other and surrounding tissue to move as they form organs in an embryo, heal wounds, track down invading bacteria, and become cancerous and spread. Led by researchers at NYU Grossman School of Medicine, the new study examined how forces are generated by a group of 140 cells called the primordium that adhere to each other as they move in zebrafish embryos. Zebrafish are a major model in the study of development because they are transparent and share cellular mechanisms with humans.

Published online December 13 in Current Biology, the new work reveals how the cells in the primordium use a protein called RhoA to trigger forces that move the group into place in the developing embryo. To move, cells push out part of themselves called protrusions, use the protrusions to hold on to nearby tissues, and then haul them back in to pull forward, like casting out and hauling in an anchor.

This finding surprised us because we had no reason to suspect that the RhoA machinery required to move groups of cells would be different from that used by single cells, said senior study author Holger Knaut, PhD, associate professor in the Department of Cell Biology at NYU Langone Health.

Past studies had shown that single cells move forward in part by activating RhoA at their back ends. Active RhoA turns on the motor protein non-muscle myosin II, which causes the back ends of the cells to constrict and let go of the surface they are moving along.

The current study found that the cells in the primordium instead activate RhoA in pulses in the front of the cells where it does two jobs. At the front tip of the cell, RhoA grows the cell skeleton, called the actin meshwork, outward, forming protrusions that grip the surface. At the base of protrusions, RhoA triggers non-muscle myosin II to pull on the actin meshwork and haul in the protrusions. The pulling by myosin II makes the actin flow toward the center and back of the cells, pushing the cell group forward the way a banana slug moves along the ground, but at a different size scale.

Our findings suggest that RhoA-induced actin flow on the basal sides of cells constitutes the motor that pulls the primordium forward, a scenario that likely underlies the movement of many cell groups, added Dr. Knaut. The machinery suggests that the movement of single cells and groups of cells is similar, but that RhoA contributes to that machinery differently in each case. Within moving cell groups, RhoA generates actin flow directed toward the rear to propel the group forward.

Dr. Knaut notes that a better understanding of the mechanisms by which cell groups move has the potential to be useful in stopping the spread of cancer, perhaps by guiding the design of treatments that block the action of proteins noted in the study.

Along with Dr. Knaut, study authors were Weiyi Qian (co-corresponding author), Naoya Yamaguchi, and Patrycja Lis in the Department of Cell Biology, and Michael Cammer from the Microscopy Laboratory, at NYU Langone Health. The study was funded by Perlmutter Cancer Center Support Grant P30CA016087, National Institutions of Health grant R01NS119449, NYSTEM training grants C322560GG and C322560GG, two American Heart Association fellowships, 903886 and 20PRE3518016, and by the NYU Deans Undergraduate Research Fund.

Experimental study

Cells

Pulses of RhoA Signaling Stimulate Actin Polymerization and Flow in Protrusions to Drive Collective Cell Migration

13-Dec-2023

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

More here:
Cells move in groups differently than they do when alone - EurekAlert

Seattle Hub for Synthetic Biology plans to transform cells into tiny recording devices – GeekWire

Jay Shendure, a professor of genome sciences at UW Medicine, will be executive director of the Seattle Hub for Synthetic Biology. (UW Medicine Photo)

The Allen Institute, the Chan Zuckerberg Initiative and the University of Washington have launched a collaboration called the Seattle Hub for Synthetic Biology, with the goal of using genetically modified cells to capture a DNA-based record showing how they change over time.

If the project works out as hoped, it could lead to a deeper understanding of the mechanisms behind cellular processes including, for example, how tumors grow and point to new methods for fighting disease and promoting healthy cell growth.

Over the next five years, the Seattle Hub for Synthetic Biology will receive $35 million from the Allen Institute, and another $35 million from the Chan Zuckerberg Initiative, founded by Meta CEO Mark Zuckerberg and his wife, Priscilla Chan.

Jay Shendure, a professor of genome sciences at UW Medicine, will serve as the hubs executive director. Other members of the leadership team include Marion Pepper and Cole Trapnell, researchers at UW Medicine; and Jesse Gray, a veteran of Ascidian Therapeutics and Harvard Medical School. The collaboration will build on technology pioneered at the Allen Discovery Center for Cell Lineage Tracing and the Brotman Baty Institute for Precision Medicine.

Shendure compared the genetically modified cells to flight recorders on airplanes. He said such cells could, for example, be combined with CAR-T cells to track the progress of cancer therapy.

You could imagine layering them into CAR-T cells to provide a record of what happened, in the context of trying to deliver a certain therapeutic, he told GeekWire. And then you could imagine components of these cells, or more sophisticated versions, actually being used as part of the therapy where, when and how a therapeutic turns on or off is modulated at some level by a much more sophisticated set of machinery.

That sort of application is far down the road. In the nearer term, SeaHubs researchers aim to develop a new channel for chronicling the changes that cells go through. This channel would take an approach thats different from existing methods that depend on microscope imaging or sequencing a cells entire genome.

Shendure and his colleagues at UW have already created two techniques that could help turn elements of the genetic machinery inside cells into tiny time-lapse recording devices.

One of the techniques, known as DNA Typewriter, was the subject of a research paper in the journal Nature last year. The system makes use of gene-editing tools to lay down short snippets of DNA in chronological order, moving along a molecular string like the clicks of the carriage on an old-fashioned typewriter.

If you insert a five-base-pair sequence, thats four to the fifth, or 1,024. So there are 1,024 possible symbols that we could insert, Shendure said. When you punch a key, so to speak, you write a symbol one of those 1,024 possible insertions. Thats like the recording of information. And the same edit moves the type head one unit down the tape. Youre not just firing letters at a piece of paper, youre actually typing them in some coherent order.

The second technique is Engram. Without Engram, DNA Typewriter is like a monkey at a typewriter, just hitting keys, Shendure said. But with Engram, at least for some of the keys, we can say youre more likely to type this key if this particular signaling pathway is active, or youre only going to type this key if youre this particular cell type. So, were starting to learn how to assign meanings to keys, and to build a vocabulary of triggers between biological signals and symbols on our keyboard.

To read the recording, researchers could extract some of the recorder cells and check the sequence of DNA letters that were inserted over time.

Early practical applications of the cell-recording technologies are likely to focus on studying how cells multiply and develop into tissues under normal conditions, and how things go wrong due to disease.

Studying the growth of a cancerous tumor would be a great example, Shendure said. If you want to probe the history of one tumor obviously this would be in a model organism, but it could be a human cell transplanted in a mouse trying to accumulate that history over time is something that you would want to do, he said.

Researchers could track the development of different tumors on the cellular level, and study how different treatment strategies affect their growth. For that scenario, a strain of mice could be genetically engineered with cell-recording capability.

We make a mouse line that essentially has all this stuff stably, and the recording device can be turned on at any point, Shendure said. You could have it constituently on, so it switches on at the beginning, or you could use a small chemical to turn it on, like doxycycline.

Such methods could also be used to fine-tune tissue engineering. If were trying to make skin in a dish, or something like that, whats working? Whats not working? And how do you modulate it to improve the process? Shendure said.

Using such techniques for clinical treatment in humans is a long-term strategy. But how long-term? I dont think theyre as futuristic as they might seem, given everything thats going on, Shendure said.

Findings from the research effort will be shared widely within the scientific community. Its all going to be open science, fitting with the philosophy of the Allen Institute and CZI, Shendure said.

The Chan Zuckerberg Initiatives backing for the Seattle Hub for Synthetic Biology builds on the philanthropic organizations history of supporting big-picture biotech projects including a $3 billion effort aimed at curing, preventing and managing all diseases within a generation, and $15 million in grants that were awarded in 2018 to support a global research effort called the Human Cell Atlas.

By developing new technologies to measure and understand the history of our cells over time, including how they are impacted by the environment around them, genetic mutations and other factors, we can expand scientists understanding of what happens at the cellular level when we go from healthy to sick, and help pinpoint the earliest causes of disease, CZI co-founder and co-CEO Priscilla Chan said in a news release.

Rui Costa, president and chief executive officer of the Allen Institute, said he and his colleagues are incredibly excited to enter this new era of collaboration to tackle big moonshot projects in partnership with others.

UW President Ana Mari Cauce said the project demonstrates the enormous potential impact of values-driven partnerships, and it represents a new way of thinking about how we can solve problems more quickly and effectively through scientific collaboration.

Our shared values, paired with our complementary perspectives and strengths, are a recipe for success, and I cant wait to see what this team will accomplish together, Cauce said.

The effort should yield noticeable results within five years, Shendure said.

It could lead to basically a library of tools for engineering cell types, specific expression, et cetera. I think therell be these deliverables that are broadly useful for the field, he said.

Shendure hopes researchers at the Seattle Hub for Synthetic Biology will come up with specific bodies of information relating to cell lineages, including cancer cell lineages, that would be impossible to obtain using more conventional technologies. But he also has a bigger goal in mind: Gaining acceptance for a new modality of measuring things over time, using DNA as a recording medium.

Thats been kind of a niche interest of technology development groups, Shendure said. Were trying to really move that toward the mainstream.

More here:
Seattle Hub for Synthetic Biology plans to transform cells into tiny recording devices - GeekWire

How to watch Anatomy of a Fall is it streaming? – Dexerto

Jasmine Valentine

Published: 2023-12-11T16:51:49 Updated: 2023-12-11T16:52:00

The thrilling French courtroom drama is drawing international attention through its Golden Globe nominations but is Anatomy of a Fall streaming?

Its been a fantastic year for German actress Sandra Hller, who has achieved international success with her roles in The Zone of Interest and courtroom drama Anatomy of a Fall.

The films synopsis reads: A woman is suspected of her husbands murder, and their blind son faces a moral dilemma as the sole witness.

Article continues after ad

With the film now nominated for multiple Golden Globes, is Anatomy of a Fall streaming? Heres everything you need to know.

Article continues after ad

Anatomy of a Fall currently isnt available on streaming, with no official streaming date announced as of yet.

In line with other Neon releases, a timeline for Anatomy of a Fall to be available on streaming can be guessed, with estimations currently placing its release around February 2024. Historically, Neon-distributed titles stream exclusively on Hulu approximately four months after their theatrical release in the United States.

Article continues after ad

Well be sure to keep this space updated with the latest streaming news for the movie.

Anatomy of a Fall is currently available to buy or rent on various digital platforms, including Apple TV and iTunes.

Article continues after ad

The movie initially received a limited theatrical release in the US on October 13, 2023, before rolling out to more cinemas nationwide in the following weeks.

Subscribe to our newsletter for the latest updates on Esports, Gaming and more.

As of writing, Anatomy of a Fall is also available to pre-order on Amazon Prime Video, which you can do so here.

Article continues after ad

According to many critics and now the Golden Globes Anatomy of a Fall is definitely worth the watch.

The movie currently has a 96% rating on the Rotten Tomatoes Tomatometer, with an audience score of 91%.

Wendy Ide of The Observer said, Ultimately, one of the key pleasures of the picture is its uncertainty the niggling doubts that remain, and the sense that a crucial piece of the puzzle is tantalizingly out of reach.

Article continues after ad

Clarissa Loughrey at The Independent agreed, Its hard not to be drawn in. Thats the trick of Anatomy of a Fall. Sandra is a fascinating, one-woman puzzle box, thanks largely to the strength of Hllers performance.

Article continues after ad

Check out our other upcoming movie and TV hubs below:

Fantastic Four|Avengers: The Kang Dynasty|Avengers: Secret Wars|Marvel Zombies|The Marvels|Agatha: Coven of Chaos |Blade MCU|Captain America 4 | The Boys Season 4 | Avatar 3|Batman: The Brave And The Bold|Beetlejuice 2|Blade|Deadpool 3|Dune 2|Gladiator 2|Mission: Impossible 8|Mortal Kombat 2|Beyond the Spider-Verse|Superman: Legacy|Thunderbolts|Venom 3|Wicked|1923 Season 2|Citadel Season 2|Daredevil: Born Again|Euphoria Season 3|Severance Season 2|Stranger Things Season 5|The Last of Us Season 2|The Mandalorian Season 4|The Penguin|The Sandman Season 2|The White Lotus Season 3|Wednesday Season 2|Yellowjackets Season 3

Article continues after ad

Article continues after ad

Please note that if you click on a product link on this page, we may earn a small affiliate commission.

See the original post here:
How to watch Anatomy of a Fall is it streaming? - Dexerto

Every ‘Grey’s Anatomy’ Season Is Coming to Hulu – Vulture

Chop chop streamers, its been 13 years. Greys Anatomy is reportedly expanding its 19-season library from just Netflix and ok, TikTok too, in the form of 30-second clips and Subway Surfers footage to Hulu as well. According to sources familiar with the licensing agreement, which is still being finalized, both services will be sharing streaming rights to the show beginning sometime in the spring of 2024, with Hulu getting dibs on the newest episodes for its 20th season. Itll arrive around the same time as the Hulu and Disney+ integration, a.k.a. when the apps finally merge and become one. It remains one of the most popular shows both on linear television and on streaming, with many people revisiting the show on social media (the hashtag #GreysAnatomy has over 51 billion views). Now, you wont have to wait for an anonymous TikTok account to publish the next Greys clip for much longer.

The deal isnt just a one-way street; it also includes some non-branded Disney shows heading to Netflix as well throughout the next year: The Wonder Years (1/1/2024), This is Us (1/8/2024), My Wife & Kids (2/5/2024), ESPN 30 for 30: (25 episodes; with various premiere dates TBD), The Resident (3/4/2024), White Collar (4/1/2024), Reba (5/6/2024), Archer (5/13/2024), How I Met You Mother (6/3/2023), Lost (7/1/2024), Prison Break (7/29/2024), Bernie Mac (1/1/2025), and Home Improvement (2/1/2025). All of these shows will continue to stay on Hulu with no plans of removing them from the platform during the expansion. Now, if we could only add sensory videos into the mix

See the original post here:
Every 'Grey's Anatomy' Season Is Coming to Hulu - Vulture